[Efficacy of keppra in combined therapy in pharmacoresistant adult epilepsy patients].
There were analyzed efficacy of keppra (Levetiracetam) in combined therapy in 31 patients with pharmacoresistant partial epilepsy and in 2 cases with idiopathic generalized epilepsy. During the 4 months 48.4% experienced at least a 50% reduction in the frequency of partial-oncet seizures, 12.9% at least a 75% reduction, and 25.8% demonstrated a seizure free. The combined therapy was ineffective only in 12.9%. The authors emphasize a good tolerability of keppra. There was only one case with side-effect, that demand cancel of Levetiracetam. The results obtained reveal effectiveness of keppra using in epileptology, in particular, in pharmacoresistant epilepsy.